A polymorphism in the OPRM1 3′-untranslated region is associated with methadone efficacy in treating opioid dependence

Pharmacogenomics Journal

Volumn 18, Issue 1, 2018, Pages 173-179

  Crist, R C ^a   Doyle, G A ^a   Nelson, E C ^b   Degenhardt, L ^c   Martin, N G ^d   Montgomery, G W ^e   Saxon, A J ^f   Ling, W ^g   Berrettini, W H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; GUANINE; METHADONE; MICRORNA; MICRORNA 95 3P; UNCLASSIFIED DRUG; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; OPRM1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ADULT; ALLELE; ARTICLE; AUSTRALIAN; CONTROLLED STUDY; DRUG EFFICACY; DRUG URINE LEVEL; EUROPEAN; EUROPEAN AMERICAN; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; OPRM1 GENE; PHARMACOGENETICS; POPULATION GENETICS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SELF REPORT; SINGLE NUCLEOTIDE POLYMORPHISM; URINALYSIS; AUSTRALIA; CAUCASIAN; GENETIC POLYMORPHISM; GENETICS; PROCEDURES;

3' UNTRANSLATED REGIONS; ADULT; ALLELES; ANALGESICS, OPIOID; AUSTRALIA; BUPRENORPHINE; BUPRENORPHINE, NALOXONE DRUG COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; MALE; METHADONE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; POLYMORPHISM, GENETIC; RECEPTORS, OPIOID, MU;

EID: 85003952293     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2016.89     Document Type: Article

References (43)

1. Degenhardt L, Charlson F, Mathers B, Hall WD, Flaxman AD, Johns N et al. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction 2014; 109: 1320-1333.
2. Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med 2011; 12: 657-667.
3. Yuferov V, Levran O, Proudnikov D, Nielsen DA, Kreek MJ. Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann NY Acad Sci 2010; 1187: 184-207.
4. Gelernter J, Kranzler HR, Sherva R, Koesterer R, Almasy L, Zhao H et al. Genomewide association study of opioid dependence: multiple associations mapped to calcium and potassium pathways. Biol Psychiatry 2014; 76: 66-74.
5. Becker A, Grecksch G, Kraus J, Loh HH, Schroeder H, Hollt V. Rewarding effects of ethanol and cocaine in mu opioid receptor-deficient mice. Naunyn Schmiedebergs Arch Pharmacol 2002; 365: 296-302.
6. Hall FS, Goeb M, Li XF, Sora I, Uhl GR. mu-Opioid receptor knockout mice display reduced cocaine conditioned place preference but enhanced sensitization of cocaine-induced locomotion. Brain Res 2004; 121: 123-130.
7. Hummel M, Schroeder J, Liu-Chen LY, Cowan A, Unterwald EM. An antisense oligodeoxynucleotide to the mu opioid receptor attenuates cocaine-induced behavioral sensitization and reward in mice. Neuroscience 2006; 142: 481-491.
8. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996; 383: 819-823.
9. Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM et al. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 1997; 94: 1544-1549.
10. Berrettini WH, Ferraro TN, Alexander RC, Buchberg AM, Vogel WH. Quantitative trait loci mapping of three loci controlling morphine preference using inbred mouse strains. Nat Genet 1994; 7: 54-58.
11. Doyle GA, Schwebel CL, Ruiz SE, Chou AD, Lai AT, Wang MJ et al. Analysis of candidate genes for morphine preference quantitative trait locus Mop2. Neuroscience 2014; 277: 403-416.
12. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; 2: CD002207.
13. Nicholls L, Bragaw L, Ruetsch C. Opioid dependence treatment and guidelines. J Manag Care Pharm 2010; 16 (1 Suppl B): S14-S21.
14. Fiellin DA, O'Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS. Methadone maintenance in primary care: A randomized controlled trial. JAMA 2001; 286: 1724-1731.
15. Pani PP, Maremmani I, Pirastu R, Tagliamonte A, Gessa GL. Buprenorphine: A controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend 2000; 60: 39-50.
16. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 2008; 65: 135-144.
17. Chamorro AJ, Marcos M, Miron-Canelo JA, Pastor I, Gonzalez-Sarmiento R, Laso FJ. Association of micro-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: A systematic review and meta-analysis. Addict Biol 2012; 17: 505-512.
18. Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts shortterm response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 2004; 4: 184-192.
19. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28: 1546-1552.
20. Clarke TK, Crist RC, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ et al. Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. Pharmacogenomics J 2014; 14: 303-308.
21. Crist RC, Clarke TK, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ et al. An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology 2013; 38: 2003-2010.
22. Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry 2014; 171: 445-452.
23. Oneda B, Crettol S, Bochud M, Besson J, Croquette-Krokar M, Hammig R et al. beta-Arrestin2 influences the response to methadone in opioid-dependent patients. Pharmacogenomics J 2011; 11: 258-266.
24. Ide S, Han W, Kasai S, Hata H, Sora I, Ikeda K. Characterization of the 3' untranslated region of the human mu-opioid receptor (MOR-1) mRNA. Gene 2005; 364: 139-145.
25. Bolognani F, Perrone-Bizzozero NI. RNA-protein interactions and control of mRNA stability in neurons. J Neurosci Res 2008; 86: 481-489.
26. Vreugdenhil E, Berezikov E. Fine-tuning the brain: MicroRNAs. Front Neuroendocrinol 2010; 31: 128-133.
27. Zhang R, Su B. Small but influential: The role of microRNAs on gene regulatory network and 3'UTR evolution. J Genet Genomics 2009; 36: 1-6.
28. Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A et al. Buprenorphine/ Naloxone and methadone effects on laboratory indices of liver health: A randomized trial. Drug Alcohol Depend 2013; 128: 71-76.
29. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
30. Crist RC, Ambrose-Lanci LM, Vaswani M, Clarke TK, Zeng A, Yuan C et al. Casecontrol association analysis of polymorphisms in the delta-opioid receptor, OPRD1, with cocaine and opioid addicted populations. Drug Alcohol Depend 2013; 127: 122-128.
31. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
32. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001; 125: 279-284.
33. Liang K-Y, Zeger S. L. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22.
34. Potter JS, Marino EN, Hillhouse MP, Nielsen S, Wiest K, Canamar CP et al. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs 2013; 74: 605-613.
35. Shand FL, Degenhardt L, Slade T, Nelson EC. Sex differences amongst dependent heroin users: histories, clinical characteristics and predictors of other substance dependence. Addict Behav 2011; 36: 27-36.
36. Nelson EC, Agrawal A, Heath AC, Bogdan R, Sherva R, Zhang B et al. Evidence of CNIH3 involvement in opioid dependence. Mol Psychiatry 2016; 21: 608-614.
37. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. PLoS Genet 2006; 2: e190.
38. Meunier J, Lemoine F, Soumillon M, Liechti A, Weier M, Guschanski K et al. Birth and expression evolution of mammalian microRNA genes. Genome Res 2013; 23: 34-45.
39. Lu Z, Xu J, Xu M, Pasternak GW, Pan YX. Morphine regulates expression of muopioid receptor MOR-1A, an intron-retention carboxyl terminal splice variant of the mu-opioid receptor (OPRM1) gene via miR-103/miR-107. Mol Pharmacol 2014; 85: 368-380.
40. Zheng H, Chu J, Zeng Y, Loh HH, Law PY. Yin Yang 1 phosphorylation contributes to the differential effects of mu-opioid receptor agonists on microRNA-190 expression. J Biol Chem 2010; 285: 21994-22002.
41. Walsh SL, June HL, Schuh KJ, Preston KL, Bigelow GE, Stitzer ML. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology 1995; 119: 268-276.
42. Burns L, Gisev N, Larney S, Dobbins T, Gibson A, Kimber J et al. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia. Addiction 2015; 110: 646-655.
43. Chan D. So why ask me Are self-report data really that bad In: Lance CE, Vandenberg R. J. (ed). Statistical and Methodological Myths and Urban Legends: Doctrine, Verity and Fable in the Organizational and Social Sciences. Taylor & Franci: New York, USA, 2009, pp 309-336.